Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sarepta Therapeutics to Present Company Overview at the 2013 31st Annual JP Morgan Healthcare Conference

SRPT
Sarepta Therapeutics to Present Company Overview at the 2013 31st Annual JP Morgan Healthcare Conference
http://media.marketwire.com/attachments/201207/48809_SareptaTherapeutics.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=969640&ProfileId=051205&sourceType=1

CAMBRIDGE, MA -- (Marketwire) -- 12/28/12 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2013 31st Annual JP Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 4:30pm Pacific Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at www.sareptatherapeutics.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.

Sarepta Media and Investor Contact:
Erin Cox
425.354.5140
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today